My 600 lb former girlfriend would look good in them!
- $800 Sweat Pants- Moncler
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
oops! wrong thread. I hate that!
I am going to have to reconsider my " On My Chin " theory
Splunk jumps 13% after WSJ report of $20B plus takeover offer from Cisco 18:37 SPLK, CSCO In after hours trading, shares of Splunk are up 13% to $129.98.
Splunk jumps 13% after WSJ report of $20B plus takeover offer from Cisco 18:37 SPLK, CSCO In after hours trading, shares of Splunk are up 13% to $129.98.
Stoney or Van what are your favorite ETFs for bonds, derivative income or high dividends?
Hey TPT,
check out DNP and USA. They are closed end funds. DNP has a large percentage utilities(communications and energy) 7% Div. They do use up to 25pc margin. Also divvy can be return of capital. Beta is 0.6ish. Has run up of late due to energy prices. Monthly divvy.
USA is more market correlated. Beta maybe more like 1.5 can’t remember exactly. 10% divvy. Quarterly.
newbie
I THINK WE ARE ALL GOING TO BE RICH MONDAY.... I THINK THE FDA SAID OK... IT WAS IN THE NY TIMES!!!
GUMMY #2! LETS MAKE VAN RICH!
AbCellera Biologics Inc. (ABCL)
9.60-0.08(-0.83%)
At close: February 10 04:00PM EST
10.09+0.49(+5.10%)<-------------------
Pre-Market:08:21AM EST
ABCL----AbCellera royalties could be 'substantial' from Lilly antibody, says Benchmark 08:15 ABCL, LLY After AbCellera (ABCL)…
OMG---
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Fri, February 11, 2022, 6:58 PM
In this article:
ABCL
+0.42%<--------WATCH MONDAY!!!!
Watchlist
- GUMMYBEARADVISORS STRIKES AGAIN! ONLY AT ELITE TRADER*****
VANCOUVER, British Columbia, February 11, 2022--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Bebtelovimab is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. The authorized dosage of bebtelovimab is 175 mg given as an intravenous injection over at least 30 seconds.
- Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data
- Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern
- Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting the potential to retain effectiveness against emerging variants
YOU ARE WELCOME !!! 